- Home
- COGT vs IRS Comparison
COGT vs IRS Comparison
Compare COGT & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- IRS
- Stock Information
- Founded
- COGT 2014
- IRS 1943
- Country
- COGT United States
- IRS Argentina
- Employees
- COGT N/A
- IRS N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- IRS Homebuilding
- Sector
- COGT Health Care
- IRS Real Estate
- Exchange
- COGT Nasdaq
- IRS Nasdaq
- Market Cap
- COGT 1.0B
- IRS 1.1B
- IPO Year
- COGT 2018
- IRS 1994
- Fundamental
- Price
- COGT $8.00
- IRS $14.15
- Analyst Decision
- COGT Buy
- IRS Strong Buy
- Analyst Count
- COGT 6
- IRS 1
- Target Price
- COGT $14.17
- IRS $12.62
- AVG Volume (30 Days)
- COGT 1.3M
- IRS 158.2K
- Earning Date
- COGT 03-04-2025
- IRS 02-07-2025
- Dividend Yield
- COGT N/A
- IRS 11.59%
- EPS Growth
- COGT N/A
- IRS N/A
- EPS
- COGT N/A
- IRS N/A
- Revenue
- COGT N/A
- IRS $325,094,048.00
- Revenue This Year
- COGT N/A
- IRS N/A
- Revenue Next Year
- COGT N/A
- IRS N/A
- P/E Ratio
- COGT N/A
- IRS N/A
- Revenue Growth
- COGT N/A
- IRS N/A
- 52 Week Low
- COGT $5.73
- IRS $7.32
- 52 Week High
- COGT $12.61
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- COGT 41.50
- IRS 46.29
- Support Level
- COGT $7.88
- IRS $13.85
- Resistance Level
- COGT $8.37
- IRS $14.40
- Average True Range (ATR)
- COGT 0.42
- IRS 0.72
- MACD
- COGT -0.11
- IRS 0.08
- Stochastic Oscillator
- COGT 5.85
- IRS 69.07
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.